PPARγ agonists regulate multiple processes, including Aβ homeostasis through the suppression of BACE1 expression, energy metabolism, insulin sensitivity, dyslipidemia, and microglial inflammatory responses [33], [34]. Here, INS is linked to metabolic syndrome.